Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity

erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 1996-07, Vol.2 (7), p.1089-1095
Main Authors: BARNES, M. N, DESHANE, J. S, SIEGAL, G. P, ALVAREZ, R. D, CURIEL, D. T
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Cisplatin - pharmacology
Down-Regulation
Female
Genetic Therapy
Humans
Immunoglobulin Fragments - genetics
Immunotherapy
Medical sciences
Neoplasms - therapy
Pharmacology. Drug treatments
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - immunology
Tumor Cells, Cultured
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 1095
container_issue 7
container_start_page 1089
container_title Clinical cancer research
container_volume 2
creator BARNES, M. N
DESHANE, J. S
SIEGAL, G. P
ALVAREZ, R. D
CURIEL, D. T
description erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2-mediated tumor cell chemoresistance.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78769870</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78769870</sourcerecordid><originalsourceid>FETCH-LOGICAL-h267t-8d605188bcea06cad74f594daa851330e7d894e12d4fd98bd3077a74ee8926d73</originalsourceid><addsrcrecordid>eNo90N9LwzAQB_AiypzTP0HIg-hTIWnaJH2U4S8Y-qLP5ZZcl0jbzCTd2H9vh8OnO7gPx933LJuzqpI5L0R1PvVUqpyWvLjMrmL8ppSVjJazbFYrJgpZzDP_7nfYkQ0OSJLFANsDiSlAws2BJE9Aa99vOxct2QS_T5a0oJMPpPdm7CA5PxA3mFFjJDhYGDQaksZ-Ehq7jmiLvY84RJfczqXDdXbRQhfx5lQX2dfz0-fyNV99vLwtH1e5LYRMuTKCVkyptUagQoORZVvVpQFQFeOcojSqLpEVpmxNrdaGUylBloiqLoSRfJHd_-3dBv8zYkxN7-LxIhjQj7GRSopaSTrB2xMc1z2aZhtcD-HQnBKa5nenOUQNXRumF138Z5wJKriY2MMfs25j9y5go49ZhIARIWjbFI1sGFU1_wV_0YBc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78769870</pqid></control><display><type>article</type><title>Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity</title><source>Freely Accessible Journals</source><creator>BARNES, M. N ; DESHANE, J. S ; SIEGAL, G. P ; ALVAREZ, R. D ; CURIEL, D. T</creator><creatorcontrib>BARNES, M. N ; DESHANE, J. S ; SIEGAL, G. P ; ALVAREZ, R. D ; CURIEL, D. T</creatorcontrib><description>erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2-mediated tumor cell chemoresistance.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 9816272</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Cisplatin - pharmacology ; Down-Regulation ; Female ; Genetic Therapy ; Humans ; Immunoglobulin Fragments - genetics ; Immunotherapy ; Medical sciences ; Neoplasms - therapy ; Pharmacology. Drug treatments ; Receptor, ErbB-2 - antagonists &amp; inhibitors ; Receptor, ErbB-2 - immunology ; Tumor Cells, Cultured</subject><ispartof>Clinical cancer research, 1996-07, Vol.2 (7), p.1089-1095</ispartof><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3160636$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9816272$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BARNES, M. N</creatorcontrib><creatorcontrib>DESHANE, J. S</creatorcontrib><creatorcontrib>SIEGAL, G. P</creatorcontrib><creatorcontrib>ALVAREZ, R. D</creatorcontrib><creatorcontrib>CURIEL, D. T</creatorcontrib><title>Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2-mediated tumor cell chemoresistance.</description><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cisplatin - pharmacology</subject><subject>Down-Regulation</subject><subject>Female</subject><subject>Genetic Therapy</subject><subject>Humans</subject><subject>Immunoglobulin Fragments - genetics</subject><subject>Immunotherapy</subject><subject>Medical sciences</subject><subject>Neoplasms - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptor, ErbB-2 - antagonists &amp; inhibitors</subject><subject>Receptor, ErbB-2 - immunology</subject><subject>Tumor Cells, Cultured</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNo90N9LwzAQB_AiypzTP0HIg-hTIWnaJH2U4S8Y-qLP5ZZcl0jbzCTd2H9vh8OnO7gPx933LJuzqpI5L0R1PvVUqpyWvLjMrmL8ppSVjJazbFYrJgpZzDP_7nfYkQ0OSJLFANsDiSlAws2BJE9Aa99vOxct2QS_T5a0oJMPpPdm7CA5PxA3mFFjJDhYGDQaksZ-Ehq7jmiLvY84RJfczqXDdXbRQhfx5lQX2dfz0-fyNV99vLwtH1e5LYRMuTKCVkyptUagQoORZVvVpQFQFeOcojSqLpEVpmxNrdaGUylBloiqLoSRfJHd_-3dBv8zYkxN7-LxIhjQj7GRSopaSTrB2xMc1z2aZhtcD-HQnBKa5nenOUQNXRumF138Z5wJKriY2MMfs25j9y5go49ZhIARIWjbFI1sGFU1_wV_0YBc</recordid><startdate>19960701</startdate><enddate>19960701</enddate><creator>BARNES, M. N</creator><creator>DESHANE, J. S</creator><creator>SIEGAL, G. P</creator><creator>ALVAREZ, R. D</creator><creator>CURIEL, D. T</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>19960701</creationdate><title>Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity</title><author>BARNES, M. N ; DESHANE, J. S ; SIEGAL, G. P ; ALVAREZ, R. D ; CURIEL, D. T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h267t-8d605188bcea06cad74f594daa851330e7d894e12d4fd98bd3077a74ee8926d73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cisplatin - pharmacology</topic><topic>Down-Regulation</topic><topic>Female</topic><topic>Genetic Therapy</topic><topic>Humans</topic><topic>Immunoglobulin Fragments - genetics</topic><topic>Immunotherapy</topic><topic>Medical sciences</topic><topic>Neoplasms - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptor, ErbB-2 - antagonists &amp; inhibitors</topic><topic>Receptor, ErbB-2 - immunology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BARNES, M. N</creatorcontrib><creatorcontrib>DESHANE, J. S</creatorcontrib><creatorcontrib>SIEGAL, G. P</creatorcontrib><creatorcontrib>ALVAREZ, R. D</creatorcontrib><creatorcontrib>CURIEL, D. T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BARNES, M. N</au><au>DESHANE, J. S</au><au>SIEGAL, G. P</au><au>ALVAREZ, R. D</au><au>CURIEL, D. T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>1996-07-01</date><risdate>1996</risdate><volume>2</volume><issue>7</issue><spage>1089</spage><epage>1095</epage><pages>1089-1095</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2-mediated tumor cell chemoresistance.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9816272</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 1996-07, Vol.2 (7), p.1089-1095
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_78769870
source Freely Accessible Journals
subjects Antineoplastic agents
Biological and medical sciences
Cisplatin - pharmacology
Down-Regulation
Female
Genetic Therapy
Humans
Immunoglobulin Fragments - genetics
Immunotherapy
Medical sciences
Neoplasms - therapy
Pharmacology. Drug treatments
Receptor, ErbB-2 - antagonists & inhibitors
Receptor, ErbB-2 - immunology
Tumor Cells, Cultured
title Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A01%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20gene%20therapy%20strategy%20to%20accomplish%20growth%20factor%20modulation%20induces%20enhanced%20tumor%20cell%20chemosensitivity&rft.jtitle=Clinical%20cancer%20research&rft.au=BARNES,%20M.%20N&rft.date=1996-07-01&rft.volume=2&rft.issue=7&rft.spage=1089&rft.epage=1095&rft.pages=1089-1095&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E78769870%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h267t-8d605188bcea06cad74f594daa851330e7d894e12d4fd98bd3077a74ee8926d73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=78769870&rft_id=info:pmid/9816272&rfr_iscdi=true